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Nuclear factor kappa B (NF-KB) modulates the expression of numerous genes via interaction
with a specific DNA sequence termed the KB site. Its activity is modulated by a cytosolic
inhibitor protein termed IKB, and its activation occurs in response to a variety of agents in
a variety of cell types, most notably B and T lymphocytes. Data presented here show that
an activity (designated complex I) that binds specifically to the KB site is induced in density-
arrested Balb/c-3T3 mouse fibroblasts by platelet-derived growth factor (PDGF), a potent
mitogen for these cells. Increased levels of complex I, as evaluated by electrophoretic mo-
bility shift assays of nuclear extracts, were observed in cells treated for 1-4 h (but not 15
min) with the BB isoform of PDGF. 12-O-tetradecanoylphorbol 13-acetate (TPA) and the
AA isoform of PDGF also stimulated this response and both isoforms, but not TPA, were
effective in cells depleted of protein kinase C. Complex I most likely is authentic NF-KB, a
p5O-p65 heterodimer, or a closely related factor because it exhibited properties characteristic
of those previously described for NF-KB including inducibility by deoxycholate and cyclo-
heximide and sensitivity to IKB. A second KB binding activity (complex II), which apparently
contained p50 homodimers, displayed limited induction by PDGF, whereas a third complex
(complex III) migrated faster than but behaved similarly to complex I. These studies
suggest that NF-KB or an NF-KB-like factor may participate in the expression of PDGF-
inducible genes.
INTRODUCTION
Hormone-mediated biological processes such as cell
proliferation and differentiation require the expression
of specific genes, a process effected by the binding of
trans-acting protein factors to regulatory gene elements.
The activities of many transcription factors are hor-
monally controlled; one such hormone-responsive factor
is nuclear factor kappa B (NF-KB),1 an activity first iden-
tified in B cells by its capacity to complex to a 10-bp
sequence present in the K light chain enhancer (the KB
site; Sen and Baltimore, 1986a,b). Activation of NF-KB
1 Abbreviations used: EGF, epidermal growth factor; EMSA, elec-
trophoretic mobility shift assay; GST, glutathionine-S-transferase; IGF-
1, insulin-like growth factor 1; NF-KB, nuclear factor kappa B; PDGF,
platelet-derived growth factor; TGF#1, transforming growth factor
#3; TPA, 12-0-tetradecanoylphorbol 13-acetate.
is accomplished by numerous agents including lipo-
polysaccharide, phytahemagglutinin, and 12-0-te-
tradecanoylphorbol 13-acetate (TPA; Sen and Balti-
more, 1986b) and entails the release of NF-KB from a
cytosolic inhibitor protein termed IKB and the sub-
sequent translocation of NF-KB to the nucleus
(Baeuerle and Baltimore, 1988a). Data from in vitro
studies suggest that dissociation of NF-KB from IKB
involves phosphorylation of IKB as IKB phosphory-
lated by purified kinases (e.g., protein kinase C) does
not bind NF-KB (Ghosh and Baltimore, 1990). It is
noted that NF-KB consists of two subunits-p5O and
p65-both of which share sequence similarity in their
DNA binding domains with the products of the rel
oncogene family (Ghosh et al., 1990; Kieran et al.,
1990; Nolan et al., 1991; Ruben et al., 1991) and that
NF-KB interacts with IKB (both the a and ,B forms) via
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p65 (Baeuerle and Baltimore, 1989; Urban and
Baeuerle, 1990; Zabel and Baeuerle, 1990).
NF-KB participates in the expression of a variety of
genes in a variety of cell types; many of these genes
encode cytokines, suggestive of a role of NF-KB in
wound healing and inflammation (reviewed by
Baeuerle, 1991). Additionally, at least in some systems,
this factor may be involved in growth control. T cell
proliferation, for example, is dependent on the expres-
sion of two NF-KB-modulated genes, interleukin-2
(Hoyos et al., 1989) and the interleukin-2 receptor a
subunit (Ballard et al., 1988; Leung and Nabel, 1988)
and is deregulated by the human leukemia virus HTLV-
1 via a process involving activation of NF-KB by a virally
encoded protein (Ballard et al., 1988; Leung and Nabel,
1988).
Although NF-KB has been extensively studied in
lymphocytes, its activity and function in fibroblasts have
been incompletely addressed. Platelet-derived growth
factor (PDGF) is a potent mitogen for fibroblasts that
like T cell mitogens (e.g., phytahemagglutinin and TPA)
promotes proliferation by initiating the cell cycle traverse
of G0-arrested cells (Pledger et al., 1977; Stem and
Smith, 1986). Biologically active PDGF is a disulfide-
linked dimer of two A chains (PDGF-AA), two B chains
(PDGF-BB, the product of the c-sis protooncogene), or
one A and one B chain and interacts with target cells
via specific membrane-bound receptors possessing an
intrinsic ligand-activated tyrosine kinase activity (re-
viewed by Olashaw et al., 1991). Binding of PDGF to
its receptors elicits the formation of a variety of second
messengers including inositol 1,4,5-trisphosphate and
diacylglycerol, which mobilize intracellular calcium and
activate protein kinase C, respectively (Olashaw et al.,
1991). Of the numerous genes transcriptionally induced
by PDGF at least three- A-interferon (Kohase et al.,
1987; Lenardo et al., 1989), melanoma growth stimu-
latory activity/gro (Bordoni et al., 1989; Anisowicz et
al., 1991) and c-myc (Kelly et al., 1983; Duyao et al.,
1990)-contain KB sites.
As PDGF both stimulates protein kinase C, a potential
meditor of NF-KB activation, and induces the expression
of genes containing KB sites, we assessed its capacity to
activate NF-KB in Balb/c-3T3 cells, a nontransformed
mouse fibroblast line. Our data show that PDGF induces
an activity (referred to as complex I) that specifically
and in an IKB-sensitive manner binds the KB site in elec-
trophoretic mobility shift assays. These data identify
NF-KB or a closely related complex as a putative and




Balb/c-3T3 and Hela cells were grown in Dulbecco-Vogt modified
Eagle's medium supplemented with 10% calf serum, 4 mM L-gluta-
mine, 50 units/ml penicillin, and 50 Ag/ml streptomycin in humidified
5% C02-95% air. Confluent cultures were used in all experiments.
WEHI 231 cells were grown in suspension and were provided by Dr.
A. Lawton (Vanderbilt University).
Preparation of Cytosolic and Nuclear Extracts
Cytosolic and nuclear extracts were prepared essentially as described
by Dignam (1983); two or three 100-mm plates of Balb/c-3T3 cells
or one of Hela cells or -5 X 106 WEHI cells were used for each
experimental treatment. Cells were rinsed with phosphate buffered
saline and scraped from the plates (Balb/c-3T3, Hela) or pelleted
(WEHI), and were lysed in Buffer A (Dignam, 1983) containing 1%
Non-idet P40. The supematant (cytosol) was collected, and the nuclear
pellet was rinsed and incubated for 2 X 15 min in a small volume of
Buffer C (Dignam, 1983) containing 0.45 M NaCl. After removal of
nuclei by centrifugation, the supematant (nuclear extract) was diluted
to give concentrations of the buffer ingredients as specified for Buffer
D (Dignam, 1983) with the exception that final KCl concentration was
50 mM. Cytosolic extracts were also adjusted to Buffer D (Dignam,
1983). All procedures were done at 4°C.
Electrophoretic Mobility Shift Assays (EMSA)
Cytosolic or nuclear extracts were preincubated for 15 min at 4°C in
a buffer containing 10 mM tis (hydroxymethyl) aminomethane (Tris)
(pH 7.5), 50 mM NaCl, 1 mM EDTA, 1.8 yg salmon sperm DNA,
0.2% NP40, and 20 Mug bovine serum albumin. Where indicated, de-
oxycholate, glutathionine-S-transferase (GST), GST/IKB or cold oli-
gonucleotide was present during the preincubation. Double-stranded
end-labeled oligonucleotide (0.25-0.5 ng/reaction) was added and
the mixture incubated for 20 min at room temperature; final sample
volume was 25 Ml. In some experiments, preimmune serum or p50
antiserum was added at this time and the samples incubated for 3 hr
at 4°C. Samples were electrophoresed on 6% polyacrylamide gels
containing 25 mM Tris, 22 mM borate, and 0.25 mM EDTA. After
electrophoresis, the gels were dried and exposed to film overnight.
Synthetic oligonucleotides were end-labeled with ['y32P]ATP and T4
polynucleotide kinase before annealing. The sequence of the wild-
type NF-KB probe was 5'-TCGACAGAGGGGACTTTCCGAGAGGC-
3' and that of the mutant oligonucleotide was 5'-TCGACAGAATT-
CACTTTCCGAGAGGC-3' (Lenardo et al., 1989).
RESULTS
Stimulation of KB Binding Activity by PDGF in
Balb/c-3T3 Cells
To determine whether PDGF stimulates KB binding ac-
tivity in Balb/c-3T3 cells, density-arrested cultures were
treated for various times with PDGF-BB or, for com-
parative purposes, TPA. Activation of NF-KB by TPA
has been observed in numerous systems (e.g., Hela [Sen
and Baltimore, 1986b]) and, like PDGF, TPA is mito-
genic for Balb/c-3T3 cells (Frantz et al., 1979). After
exposure of cells to PDGF-BB or TPA, nuclear extracts
were prepared and electrophoretic mobility shift assays
(EMSA) performed with a radiolabeled oligonucleotide
containing the KB site of the K light chain gene (Lenardo
et al., 1989). As a positive control, nuclear extracts of
TPA-treated Hela cells were also assayed.
As shown in Figure 1, A and B, exposure of Balb/c-
3T3 cells to PDGF-BB or TPA for 1-4 h stimulated the
formation of a DNA/protein complex (designated com-
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plex I) that migrated in the gel at the same position as
a complex present in TPA-treated but not untreated
Hela cells. This band shift presumably represents spe-
cific binding to the KB site because it was abolished by
excess unlabeled wild-type oligonucleotide but was un-
affected by excess oligonucleotide containing a mutation
in the KB site that precludes NF-KB binding (Figure 1C;
Lenardo et al., 1989). The kinetics of complex I formation
by PDGF-BB and TPA were similar and co-treatment
of cells for 4 h with both agents did not increase binding
activity above that induced by either agent alone (Figure
1A). It is noted that although protein kinase C is acti-
vated within minutes of addition of PDGF-BB and TPA
to cells, as is the PDGF receptor tyrosine kinase in re-
sponse to PDGF-BB (Rodriguez-Pena and Rozengurt,
1985; Kazlauskas et al., 1988), KB binding activity at 15
min after stimulation was not detectably increased
above basal level. The reason for this delay is unclear.
Two additional KB binding complexes (designated II
and III) were also seen in Balb/c-3T3 cells (Figure 1).
Although present to a lesser extent than complex I,
complex III displayed similar kinetics of induction as
did complex I and was effectively completed by excess
wild-type but not mutant oligonucleotide. Complex II,
which (for the most part) exhibited higher basal levels
than complexes I and III, was only minimally elevated
by PDGF-BB and TPA and only partially competed.
This incomplete competition may reflect the presence
of both a specific and a nonspecific DNA binding activity
in this band shift.
Specificity of KB Binding Activity in Balb/c-3T3
Cells
To assess whether stimulation of KB binding activity
was restricted to specific factors or was a generalized
response to growth factor treatment, we exposed Balb/
c-3T3 cells to epidermal growth factor (EGF), insulin-
like growth factor 1 (IGF-1) and transforming growth
factor f31 (TGFI31), as well as both the BB and AA iso-
Figure 1. Stimulation of KB binding activity by PDGF-BB and TPA.
(A) Density-arrested Balb/c-3T3 cells were prestarved overnight in
medium containing 0.5% calf serum. Prestarved cells then received
either no addition (lane 1), PDGF-BB (final concentration 20 ng/ml;
lanes 2-5), TPA (final concentration 200 nM; lanes 6-9), or PDGF-
BB and TPA (both; lane 10) for the indicated times. Nuclear extracts
were prepared and 5 ,ug analyzed for KB-binding activity by EMSA.
(B) Nuclear extracts of Balb/c-3T3 (10 Lg) and Hela (3 ,ug) cells were
assayed for KB binding activity. Hela cells were treated with (lane 2)
or without (lane 1) 200 nM TPA for 1 h. Balb/c-3T3 cells were treated
with 20 ng/ml PDGF-BB (lane 4) or 200 nM TPA (lane 5) for 2 h or
left untreated (lane 3). (C) Nuclear extracts (2 tcg) prepared from un-
treated Balb/c-3T3 cells (lane 1) or cells treated with 20 ng/ml PDGF-
BB for 2 h (lanes 2-10) were assayed for KB binding activity in the
absence (lanes 1 and 2) or presence of excess wild-type (lanes 7-10)
or mutant (lanes 3-6) oligonucleotide. Complexes I, II, and III are
indicated.
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Figure 2. Specificity of PDGF-BB in-
* WF*duction of KB-binding activity. Den-
sity-arrested Balb/c-3T3 cells were
refed with medium containing 0.25%
platelet-poor plasma (vehicle; lane 1)
and either 100 ng/ml PDGF-BB (lane
2), 100 ng/ml PDGF-AA (lane 3), 50
-A = s=ng/ml EGF (lane 4), 10 ng/ml TGF#l
(lane 5), or 50 ng/ml IGF-1 (lane 6).
Cells were harvested 4 h after refeed-
ing. Nuclear extracts (10 ug) were an-
alyzed for KB binding activity by
EMSA. Upper arrow denotes complex
I, lower arrow denotes complex III.
forms of PDGF, for 4 h. Nuclear extracts were prepared
and EMSA was performed. Whereas TPA and PDGF
act to initiate the cell-cycle traverse of GO-arrested Balb/
c-3T3 cells (Pledger et al., 1977; Frantz et al., 1979),
EGF and IGF-1 are required for traverse of early and
late G1, respectively (Leof et al., 1982, 1983); TGF3,
while mitogenic for some fibroblast lines (Leof et al.,
1986), has no effect on the proliferation of Balb/c-3T3
cells (Pledger, unpublished data). The data in Figure 2
show that EGF and PDGF-AA, like PDGF-BB, stimu-
lated KB binding (complexes I and III) whereas IGF-I
and TGF(31, at least during a 4-h treatment, did not
appreciably induce this response; thus, induction of KB-
binding activity in Balb/c-3T3 cells may to be limited,
at least in part, to factors functioning early in Go /G1.
Effect of TPA Pretreatment on PDGF-Stimulable KB
Binding Activity
As noted above, TPA and PDGF-BB, when added in
combination to cells, stimulated KB binding activity to
an extent comparable to that produced by either agent
alone (Figure 1A). This lack of additivity suggests that
these agents induce this response by a similar mecha-
nism, a premise supported by the similar time courses
shown in Figure 1A. As the actions of TPA are mediated
by protein kinase C (Castagna et al., 1982), an enzyme
previously shown to inactivate IKB in vitro (Ghosh and
Baltimore, 1990), we asked whether this kinase was re-
quired for the induction of KB binding activity by PDGF.
In these experiments, cells were pretreated for 48 h with
400 nM TPA before addition of PDGF-BB, PDGF-AA,
or TPA. Prolonged exposure of cells to TPA has been
shown previously to abrogate protein kinase C activity
(Rodriguez-Pena and Rozengurt, 1984), a phenomenon
verified in our system by immunoblotting of the protein
kinase C isozymes (all isozymes detectable in untreated
Balb/c-3T3 cells [a, 3, 6, e] were not observed in TPA-
pretreated cells; Coats, Pledger, and Mochly-Rosen,
unpublished data). As shown in Figure 3, TPA induced
KB binding activity (complexes I and III) in nonpretreated
cells but, consistent with the loss of protein kinase C
activity, was ineffective when readded to TPA-pre-
treated cells. In contrast, PDGF-BB and PDGF-AA
stimulated this response as efficiently in pretreated cells
as in control cells. Thus, the data show that the PDGF
isoforms, unlike TPA, retain the capacity to induce KB
binding in protein kinase C-depleted cells and suggest
that agents other than or in addition to protein kinase
C mediate this action of PDGF.
Involvement of IKB in the Activation
of PDGF-Inducible KB Binding Activity
Although the first identified, NF-KB is not the only factor
capable of binding the KB site (Baeuerle, 1991). Thus
whether any of the activities in our system represent
authentic NF-KB is not clear. Factors binding the KB site
include those whose activity is modulated by lKB (e.g.,
NF-KB and c-Rel, the product of the rel protooncogene)
and those whose activity is unaffected by this inhibitor
(e.g., KBF1, a p50 homodimer). With regard to this dis-
tinction, the data presented in Figure 4 support an in-
volvement of IKB in the regulation of two of the KB
binding activities (complexes I and III) in Balb/c-3T3
cells. As shown in Figure 4A, exposure of cytosol from
quiescent unstimulated Balb/c-3T3 cells to concentra-
tions of deoxycholate up to 0.5% increased progressively
the formation of complex I (or of a complex with similar
mobility as complex I). Previous studies have shown
control TPA-pretreoted
- TPA 8 MA - TPA BB AA
Figure 3. Effect of protein kinase C depletion on PDGF induction
of KB binding activity. Density-arrested Balb/c-3T3 cells were incu-
bated in medium containing either 400 nM TPA (lanes 5-8) or 2%
platelet-poor plasma and vehicle (lanes 1-4) for 48 h. Cells were
either left untouched (lanes 1 and 5) or were refed with medium
containing 2% platelet-poor plasma and either 400 nM TPA (lanes 2
and 6), 10 ng/ml PDGF-BB (lanes 3 and 7), or 10 ng/ml PDGF-AA
(lanes 4 and 8). Cells were harvested 4 h after refeeding. Nuclear
extracts (8.5 ,g) were examined for KB binding activity by EMSA.
Upper arrow denotes complex I, lower arrow denotes complex III.
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Figure 4. Deoxycholate and cycloheximide induction of KB binding activity. (A) Cytosolic extracts were prepared from density-arrested
prestarved Balb/c-3T3 cells as described in MATERIALS AND METHODS. Before addition of the labeled KB probe cytosol (13 Ag) was
preincubated for 15 min at 4°C in binding buffer supplemented with 0-0.8% deoxycholate (lanes 3-10). Final Non-idet P40 concentration in
the reaction mixture was 0.2%. Nuclear extracts were prepared from untreated (lane 1) or PDGF-BB-treated (20 ng/ml, 2 h; lane 2) Balb/c-
3T3 cells; 5.7 ,g were used in the binding assay. (B) Density-arrested prestarved Balb/c-3T3 cells received either no addition (v; lane 1) or 10
,ug/ml cycloheximide (lanes 2-6) for the indicated times. Nuclear extracts (7.8 ug) were assayed for KB-binding activity by EMSA. Complexes
I, II, and III are indicated.
that deoxycholate activates NF-KB by disrupting the NF-
KB/IKB complex (Baeuerle and Baltimore, 1988b); acti-
vation of c-Rel KB binding activity by this detergent has
also been observed (Kerr et al., 1991). The deoxycholate-
inducible KB binding activity was ablated by wild-type
but not mutant oligonucleotide and, in accord with pre-
vious findings of Baeuerle and Baltimore (1988b), was
inhibited by concentrations of deoxycholate >0.5%
(Figure 4A). Complex II was also present in Balb/c-3T3
cytosol but was not increased by deoxycholate, whereas
complex III was not detected.
Cycloheximide, which has been shown to activate
NF-KB in a variety of cell types presumably by pre-
venting resynthesis of IKB which when dissociated from
NF-KB is unstable (Sen and Baltimore, 1986b; Baeuerle
and Baltimore, 1988a), also stimulated KB binding in
Balb/c-3T3 cells (Figure 4B). Increased formation of
complexes I and III, but not complex II, was evident
and progressive in cells treated for 1-6 h with this pro-
tein synthesis inhibitor.
To directly assess the capacity of IKB to interact with
the KB binding activities in our system, nuclear extracts
of Balb/c-3T3 cells were incubated with a glutathione-
S-transferase/IKB (GST/IKB) fusion protein. This protein
was prepared using the IKB cDNA (termed MAD-3)
cloned by Haskill et al. (1991) from adherent human
monocytes (Kowalik and Huang, unpublished data), and
it is noted that inhibition of NF-KB/DNA binding by in
vitro translated MAD-3 has been demonstrated previ-
ously and apparently occurs via interaction of the MAD-
3 protein with the p65 subunit of NF-KB (Haskill et al.,
1991). Regardless of whether nuclear extracts were pre-
pared from PDGF-BB-treated, TPA-treated or untreated
cells, inclusion of GST/IKB in the binding reaction vir-
tually abolished the band shifts corresponding to com-
plexes I and III, whereas GST alone had no effect (Figure
5). This finding indicates that these complexes contain
a component (e.g., p65 or c-Rel) that binds IKB in a
manner that precludes interaction with the KB site. In
contrast, the binding of complex II to this site was not
affected by the lKB fusion protein.
Recognition of Complex II by an Antiserum to p50
The KB-binding activities in Balb/c-3T3 cells were fur-
ther characterized by use of an antipeptide antiserum
to mouse p50 (Ghosh et al., 1990). This antiserum does
not recognize c-Rel and has a preferential affinity for
p50 homodimers as compared with p5O-p65 heterodi-
mers (Sen, personal communication). In our experi-
ments, this antiserum was added to nuclear extracts after
the binding reaction; the presence of p50 in the extracts
is indicated by the appearance of a low mobility band
shift (or supershift) representing the antibody/antigen/
oligonucleotide complex, and the concomitant loss of
the corresponding higher mobility band. Nuclear ex-
tracts of Balb/c-3T3 cells and, as a positive control, un-
treated WEHI 231 mouse B cells were assayed; previous
studies have shown that WEHI cells constitutively ex-
press NF-KB (Sen and Baltimore, 1986a).
As shown in Figure 6, WEHI nuclear extracts con-
tained two KB binding activities: 1) a faster migrating
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Figure 5. Inhibition of complex I and III KB binding activity by IKB
fusion protein. Density-arrested Balb/c-3T3 cells were prestarved
overnight in medium containing 0.5% calf serum. Prestarved cells
were then received either no addition (lanes 1, 4, and 7), PDGF-BB
(final concentration 20 ng/ml; lanes 2, 5, and 8) or TPA (final con-
centration 200 nM; lanes 3, 6, and 9) for 2 h. Nuclear extracts (6 ,g)
were preincubated in binding buffer alone (lanes 1-3) or containing
GST (lanes 4-6) or GST/IKB (200 ng/rxn; lanes 7-9) for 15 min before
addition of labeled KB probe. Complexes I, II, and III are indicated.
form that was unaffected by GST/IKB but supershifted
by p50 antiserum 2) a slower migrating form that was
abolished by GST/IKB but unaffected by p50 antiserum.
These findings are consistent with the presence of p50
homodimers, which do not bind MAD-3/IKB (Haskill
et al., 1991), in the faster migrating complex and of p50-
p65 heterodimers in the slower migrating complex. The
faster migrating complex in WEHI extracts comigrated
with complex II in Balb/c-3T3 extracts, whereas the
slower migrating complex ran slightly faster than com-
plex I.
Addition of p50 antiserum to nuclear extracts of
PDGF-treated Balb/c-3T3 cells supershifted (at least in
part) complex II; this supershifted band comigrated with
the supershift seen in antiserum-treated WEHI extracts.
Preimmune serum did not produce a supershift in either
cell line and complexes I and III in Balb/c-3T3 cells
were unaffected by the p50 antiserum. These findings
indicate that complex II contains authentic p5O; whether
p50 is also present in complexes I and III in combination
with IKB-sensitive factors is not clear but not unlikely.
DISCUSSION
Our studies show that PDGF induces three specific KB-
binding activities in density-arrested Balb/c-3T3 cells
(Figure 1). These complexes have been termed complex
I, II, and III in order of decreasing mobility in native
gels. Similar complexes have been observed in serum-
treated Balb/c-3T3 cells (Baldwin et al., 1991). As eval-
uated by EMSA of nuclear extracts with a radiolabeled
oligonucleotide probe containing the KB site, complex I
was the most dramatically increased by PDGF, whereas
complex II showed only limited induction. On the basis
of the data presented and as discussed below, we sug-
gest that complex I is NF-KB (i.e., a p50-p65 heterdimer)
or a closely related complex, whereas complex II is, at
least in part, KBF1 (p50 homodimer). With regard to
complex III, its similar pattern of induction as but greater
mobility than complex I and its low abundance suggest
that this complex is a proteolytic product of complex I.
The capacity of a 42-kd fragment of p50 to dimerize
with p65 and bind the KB site has been demonstrated
previously (Baeuerle and Baltimore, 1989).
The salient feature of NF-KB is modulation of its ac-
tivity by the cytosolic protein IKB. Two forms of IKB,
termed lKB-a and lKB-fl, have been identified (Zabel and
Baeuerle, 1990) and both, although structurally and im-
munologically distinct (Kerr et al., 1991), interact with
p65 and not p50 (Baeuerle and Baltimore, 1989; Urban
and Baeuerle, 1990; Zabel and Baeuerle, 1990). As noted
above, activation of NF-KB requires its release from IKB
(Baeuerle and Baltimore, 1988a); a method of activation
involving modification but not dissociation of IKB has
also been proposed (Kerr et al., 1991). Both complex I
and complex III contained a component sensitive to IKB.
Balb/c-3T3 WEHI 231
- PDGF-BB no addition
- pi p50 IKB pi p50
1~0
Figure 6. Recognition of complex II by p50 antiserum. Nuclear ex-
tracts were prepared from untreated WEHI 231 cells (lanes 5-8) and
density-arrested prestarved Balb/c-3T3 cells either untreated (lane 1)
or treated with 20 ng/ml PDGF-BB for 2 h (lanes 2-4). Balb/c-3T3
extracts (2 Atg) and WEHI extracts (2 Ag) were preincubated in binding
buffer alone (lanes 1-5, 7, and 8) or containing GST/IKcB (lane 6) for
15 min before addition of labeled probe. Extracts then received either
no addition (lanes 1, 2, 5, and 6), 1 Ml preimnmune serum (pi; lanes 3
and 7) or 1-Mil p50 antiserum (p50; lanes 4 and 8) and were incubated
on ice for 3 h. The Balb/c-3T3 bands were overexposed to allow
detection of the supershift. Complexes I, II, and III in Balb/c-3T3
cells are indicated. Large arrow denotes supershift.
Molecular Biology of the Cell1136
PDGF Induction of KB Binding Activity
As shown in Figure 5, the binding of these complexes
to the KB site was ablated by a GST/IKB fusion protein
prepared from the cDNA encoding the IKB protein
cloned from human monocytes (MAD-3; Haskill et al.,
1991). Additionally, agents known to preclude NF-KB/
IKB interaction induced the formation of complex I (de-
oxycholate and cycloheximide) and complex III (cyclo-
heximide; Figure 4).
Both p50 and p65 are part of a rapidly growing family
of Rel-related KB-binding proteins that includes v-Rel,
c-Rel, RelB, p5OB, and the Drosophila protein dorsal
(Ballard, et al., 1990; Kabrun et al., 1990; Inoue et al.,
1991; Ip et al., 1991; Ryseck et al., 1992; Bours et al.,
1992) and previous studies (Bours et al., 1992; Ryseck
et al., 1992) have shown that many of these proteins
dimerize with each other, at least in vitro, to produce a
variety of transcriptionally active DNA binding com-
plexes. As MAD-3 (the IKB used in our study) is related
to IKB-f (Davis et al., 1991; Inoue et al., 1992), and as
IKB-# has been shown to interact with c-Rel (Kerr et al.,
1991), it is possible that the lKB-sensitive component of
complexes I and III is c-Rel and not p65. Bull et al. (1989),
however, have shown that c-rel mRNA is barely de-
tectable in quiescent NIH-3T3 cells. Although both c-
rel message and c-Rel are induced rapidly by TPA in
NIH-3T3 cells, our data show that cycloheximide in-
creases the formation of complexes I and III in Balb/c-
3T3 cells (Figure 4B) and thus suggest that these com-
plexes do not contain c-Rel as its synthesis would be
precluded by cycloheximide.
Although the presence of p65 in complexes I and III
remains unproven, data from immunological studies
indicate that complex II contains p50 (Figure 6). The
presence of p50 homodimers in complex II is consistent
with the lack of effect of 1) GST/IKB on its KB binding
activity (Figure 5) 2) deoxycholate and cycloheximide
on its induction (Figure 4). The existence of KBF1 (p50
homodimer) in various cell types and its capacity to
bind specific KB motifs and modulate transcription have
been demonstrated previously (Baldwin and Sharp,
1987; Israel et al., 1987; Fujita et al., 1992). As noted
above, the p50 antiserum used in our experiments pref-
erentially recognizes homodimerized as compared with
heterodimerized p50. Thus, the lack of effect of this
antiserum on complexes I and III does not exclude the
existence p50 in these complexes. As shown in Figure
6, this antiserum only supershifted an IKB-insensitive
KB binding activity (presumably KBF1) in WEHI cells,
a B cell line known to possess p50-p65 heterodimers
(presumably, at least in part, the IKB-sensitive band shift
in Figure 6; Sen and Baltimore, 1986a; Inoue et al., 1991).
As p50 is present in our cells, it is likely that it interacts
with proteins other than itself to form additional KB-
binding complexes (e.g., complex I and complex III).
Regardless of the identity of the KB-binding activities
in our system, our data show that two of these activities
(complexes I and III) are effectively induced by PDGF
in density-arrested Balb/c-3T3 cells. Data examining
the growth-factor specificity of this response (Figure 2)
suggest that it may be limited to factors functioning in
early Go/G1. Similarly, a role of NF-KB-like activity in
the Go/Gl transition of serum-stimulated Balb/c-3T3
cells has been proposed (Baldwin et al., 1991). Our data
also demonstrate that both the AA and BB isoforms of
PDGF enhance KB-binding activity in quiescent Balb/
c-3T3 cells (Figures 2 and 3). Previous studies (Hart et
al., 1988; Heldin et al., 1988) have shown that whereas
PDGF-BB interacts with both a and A PDGF receptors,
PDGF-AA recognizes a receptors only; thus, the ability
of PDGF-AA to stimulate KB binding activity indicates
that a receptors are capable of generating this response.
As noted above, activation of NF-KB requires its re-
lease from IKB, a process most likely accomplished by
phosphorylation of IKB. Kinases potentially responsible
for IKB phosphorylation in vivo include protein kinase
C and cyclic AMP-dependent protein kinase, both of
which have been shown to activate NF-KB in in vitro
assays and to phosphorylate one or both forms of IKB
(Shirakawa and Mizel, 1989; Ghosh and Baltimore,
1990; Kerr et al., 1991). Although PDGF-BB and PDGF-
AA activate protein kinase C (Kazlauskas et al., 1988),
down regulation of protein kinase C activity by chronic
exposure of cells to TPA did not affect subsequent in-
duction of KB binding activity by either isoform (Figure
3). Similarly, as reported by others (Meichle et al., 1990;
Bomsztyk et al., 1991), ablation of protein kinase C ac-
tivity by either TPA pretreatment or specific inhibitors
did not preclude NF-KB activation in B cells by inter-
leukin-1 or lipopolysaccharide or in T cells by tumor
necrosis factor. In these studies as well as ours, TPA
stimulated KB binding in the presence but not the ab-
sence of protein kinase C activity; thus both protein
kinase C-independent and -dependent pathways may
participate in this process. It is possible of course that
residual protein kinase C activity or TPA-insensitive
forms of this kinase account for the PDGF induction of
KB-binding activity in TPA-pretreated cells.
PDGF stimulation of KB binding most likely is also
independent of cyclic AMP-dependent protein kinase
because 1) PDGF does not appreciably increase cellular
cyclic AMP content in Balb/c-3T3 cells (Wharton et al.,
1982) 2) cyclic AMP agonists only marginally stimulated
KB binding activity (Olashaw, unpublished data). Direct
phosphorylation of IKB by the PDGF receptor tyrosine
kinase remains a possibility because some forms of IKB
have been shown to possess a consensus site for tyrosine
kinase phosphorylation (Davis et al., 1991; Haskill et
al., 1991). Our preliminary data show that vanadate,
an inhibitor of tyrosine phosphatases, increases KB
binding activity (complexes I and III) in Balb/c-3T3 cells;
whether this reflects tyrosine phosphorylation of IKB,
PDGF receptors, or other substrates is not known. Al-
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temative to IKB phosphorylation, a mechanism of NF-
KB activation by oxidation-reduction has also been pro-
posed (Staal et al., 1990; Toledano and Leonard, 1991).
PDGF has been shown to modulate the expression
of a wide variety of genes and, therefore, presumably
regulates the activity of a numerous transcription fac-
tors. Studies thus far have identified c-fos and c-jun as
PDGF-inducible trans-acting factors and have shown
that PDGF controls the activity of these factors at the
level of transcription (reviewed by Ransone and Verma,
1990). The data presented here potentially add another
trans-acting factor-NF-KB (or an NF-KB-like factor)-
to this list. Obviously further studies are required to
determine whether the stimulation of NF-KB-like activity
by PDGF is accompanied by transactivation. Identifi-
cation of specific genes induced by PDGF via the KB
site will aid in assessing the role of NF-KB-like factors
in growth control.
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